L. M. Walker

Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2

This study identifies infection-enhancing antibodies targeting the N-terminal domain of SARS-CoV-2 spike protein, which persist in convalescent patients and may be counteracted by viral mutations.

Characterization of SARS-CoV-2 Convalescent Patients' Serological Repertoire Reveals High Prevalence of Iso-RBD Antibodies

This study characterizes the serological repertoire of SARS-CoV-2 convalescent patients, revealing a high prevalence of iso-RBD antibodies that do not recognize prefusion-stabilized S, and shows that vaccination with prefusion-stabilized S reduces their prevalence.

Toxin-mediated downregulation of absorptive ion transporters NHE3, DRA, and SGLT1 in the colon contributes to diarrhea associated with Clostridioides difficile infection.

This study shows CDI reduces NHE3, DRA, and SGLT1 in the colon, impairing ion transport and causing osmotic diarrhea.

Loss of altruism in the social amoeba Dictyostelium discoideum is associated with the G protein-coupled receptor grlG

The paper identifies genomic changes in Dictyostelium discoideum that correlate with the loss of cooperation and altruism, highlighting the role of the grlG gene.

Evolution of antibody immunity following Omicron BA.1 breakthrough infection

This study tracks antibody responses six months after Omicron BA.1 breakthrough infection and finds reduced neutralizing antibodies and memory B cells, with public clones dominating and predicting new sublineages.

Therapeutic neutralizing monoclonal antibody administration protects against lethal viscerotropic Yellow Fever infection

Therapeutic monoclonal antibodies prevent death from YFV infection.

Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection

BA.1 breakthrough infection activates pre-existing memory B cells with broad activity against SARS-CoV-2 variants.

A broad and potent neutralization epitope in SARS-related coronaviruses

The paper identifies a broadly neutralizing epitope in SARS-related coronaviruses that is effective against variants, including Omicron, and suggests its use for universal vaccine design.

A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related viruses

The paper identifies a YYDRxG motif in antibodies that broadly neutralize SARS-CoV-2 variants and related viruses, suggesting a conserved epitope targeting strategy.

Genotype-specific Features Reduce the Susceptibility of South American Yellow Fever Virus Strains to Vaccine-Induced Antibodies

This study shows that South American yellow fever virus strains are less susceptible to vaccine-induced antibodies due to genetic changes in the glycoprotein E.

Single-Cell Profiling of the Antigen-Specific Response to BNT162b2 SARS-CoV-2 RNA Vaccine

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection

This paper develops a human antibody cocktail, MBP134, that provides broad protection against multiple ebolaviruses, showing enhanced efficacy in guinea pigs compared to individual antibodies.

Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates

This paper demonstrates that a two-antibody cocktail (MBP134AF) provides broad therapeutic protection against multiple ebolaviruses in ferrets and nonhuman primates.

Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody

The paper determines the structure of a broadly neutralizing antibody against ebolavirus, identifies a conserved epitope, and explains factors affecting its activity against related viruses.